X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Indian share markets slip further 
(Fri, 31 May 01:30 pm) 
 
As selling intensified across index heavy-weights, Indian share markets slipped deeper in the red in the post-noon trading session. Barring IT and pharma, all the sectoral indices are trading in the red with realty, oil and gas and FMCG stocks being the biggest losers.

BSE-Sensex is down 290 points and NSE-Nifty is trading 92 points down. BSE Mid Cap is trading 0.8% down and BSE Small Cap index is trading down by 0.7%. The rupee is trading at 56.6 to the US dollar.

As per the Central Statistical Organization (CSO), India's Gross Domestic Product (GDP) grew by 4.8% in March 2013 quarter. This was marginally better than a growth of 4.7% recorded in December 2012 quarter. Barring mining, that saw its output contract by 3.1%, all the other sectors posted growth in the March 2013 quarter. The manufacturing sector grew by 2.6%, agriculture, forestry & fishing sector grew by 1.4% whereas financing, insurance, real estate and business services sector increased by a steep 9.1% during the quarter. For the full year FY13, GDP grew by 5% on the back of strong growth of over 6% recorded by each of the trade, hotels, transport & communication and finance, insurance, real estate & business services industries. Manufacturing and agriculture reported a tepid growth of 1% and 1.9% respectively while mining output was down by 0.6% in FY13.

Domestic pharma stocks are trading mixed with Torrent Pharma and Wockhardt Ltd leading among the pack of gainers while Orchid Ltd and Aurobindo Pharma are the leading losers. Cadila Healthcare declared its March 2013 quarter results. Total sales grew by 16% YoY led by growth in exports and domestic segment. Cadila's subsidiary Zydus Wellness witnessed healthy growth of 26% YoY for the quarter. On the exports front, emerging markets registered healthy growth of 86% for the quarter. The operating margins declined by 2.5% due to increase in the operating expenditure, which grew by 19% YoY for the quarter. PAT grew by 54% YoY on back of MAT (Minimum alternative tax) credit availed during the quarter. This resulted in an improvement in net margin by 4.1% for the quarter. Cadila stock was trading up by 1.34%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Indian share markets slip further". Click here!

  
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Jul 24, 2017 01:58 PM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS